title: Atenolol in migraine prophylaxis a double-blind cross-over multicentre study.
authors.forename: V
authors.initials: V
authors.lastname: Johannsson
authors.forename: L R
authors.initials: LR
authors.lastname: Nilsson
authors.forename: T
authors.initials: T
authors.lastname: Widelius
authors.forename: T
authors.initials: T
authors.lastname: Jäverfalk
authors.forename: P
authors.initials: P
authors.lastname: Hellman
authors.forename: J A
authors.initials: JA
authors.lastname: Akesson
authors.forename: B
authors.initials: B
authors.lastname: Olerud
authors.forename: C L
authors.initials: CL
authors.lastname: Gustafsson
authors.forename: A
authors.initials: A
authors.lastname: Raak
authors.forename: G
authors.initials: G
authors.lastname: Sandahl
mesh_terms: D000328:Adult; D001262:Atenolol / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000517:prevention & control*
chemical_list: D001262:Atenolol